Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronique Litalien

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Blood Neoplasia|October 27, 2025
MNT: a new target for AMLKarla C Fischer, Veronique Litalien, Sarah T Diepstraten, et al.
Blood|March 29, 2023
STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemiaCedric S Tremblay, Jesslyn Saw, Jacqueline A Boyle, et al.
Nature Communications|December 5, 2020
Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cellsCedric S Tremblay, Sung Kai Chiu, Jesslyn Saw, et al.
Nature Communications|February 20, 2021
Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cellsCedric S Tremblay, Sung Kai Chiu, Jesslyn Saw, et al.
Cancer Cell|April 26, 2024
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancersSarah T Diepstraten, Yin Yuan, John E La Marca, et al.
Blood|October 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaDonia M Moujalled, Fiona C Brown, Chong Chyn Chua, et al.
Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.
Cancer Discovery|March 21, 2022
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AMLJessica M Salmon, Izabela Todorovski, Kym L Stanley, et al.
Blood|April 7, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasRachel Thijssen, Sarah T Diepstraten, Donia Moujalled, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Blood Neoplasia|October 27, 2025
MNT: a new target for AMLKarla C Fischer, Veronique Litalien, Sarah T Diepstraten, et al.
Blood|March 29, 2023
STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemiaCedric S Tremblay, Jesslyn Saw, Jacqueline A Boyle, et al.
Nature Communications|December 5, 2020
Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cellsCedric S Tremblay, Sung Kai Chiu, Jesslyn Saw, et al.
Nature Communications|February 20, 2021
Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cellsCedric S Tremblay, Sung Kai Chiu, Jesslyn Saw, et al.
Cancer Cell|April 26, 2024
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancersSarah T Diepstraten, Yin Yuan, John E La Marca, et al.
Blood|October 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaDonia M Moujalled, Fiona C Brown, Chong Chyn Chua, et al.
Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.
Cancer Discovery|March 21, 2022
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AMLJessica M Salmon, Izabela Todorovski, Kym L Stanley, et al.
Blood|April 7, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasRachel Thijssen, Sarah T Diepstraten, Donia Moujalled, et al.
Pageof 1